Biopharmaceutical company Gilead Sciences Inc (NasdaqGS:GILD) stated on Monday the use of the LogPad System on the Phase 4 TERISA trial that measured the antianginal
effect of Ranolazine in T2DM patients in the therapeutic areas of cardiology and endocrinology.
TERISA, conducted in 105 centers in 14 countries, was a randomized, double-blind, placebo-controlled trial in 927 type 2 patients with CAD and stable angina who had symptoms despite treatment with one or two other antianginal
Therefore, the treatment with lovastatin in addition to conventional antiaggregant and antianginal
treatment of patients with CAD and dyslipidemia had improved myocardial remodeling.
and cardio-protective effects of Terminalia arjuna, an indigenous drug in coronary artery disease.
Yet, symptoms can be invalidating and refractory to conventional antianginal
treatment with nitrates, beta-blockers and calcium-antagonists.
EECP offers patients the option of a noninvasive nonpharmacologic therapy for management of chronic chest pain, and one that results in reduced need for antianginal
Topoi et al (3) showed that a 3- to 5-day infusion of hirudin with aspirin and standard oral antianginal
therapy produced greater improvement in average and minimal cross-sectional area, minimal luminal diameter, and percentage diameter stenosis than with heparin, particularly at intermediate infusion doses of 0.
As a result, a large number of women with noncardiac chest pain end up undergoing a detailed cardiovascular work-up and receiving antianginal
drugs and even revascularization procedures without symptomatic improvement, said Dr.
Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal
A standardized questionnaire developed by APACR investigators was used to collect the following individual-level information: demographic variables, including age, race, sex, and highest education level; medication uses, including antianginal
medication, antihypertensive medication, and antidiabetic medication; and physician-diagnosed chronic disease history, including cardiovascular disease (CVD; revascularization procedures and myocardial infarction), hypertension, and diabetes.
More than 60% of patients respond to conventional antianginal
drugs have not shown the ability to reduce coronary events, so demonstrating that ivabradine does sets it apart.